Summary of Intuitive Surgical, Inc. Q3 2025 Earnings Call

1Key Financial Results and Metrics

Revenue: Q3 revenue grew 23% year-over-year to $2.51 billion.

Earnings: Pro forma net income was $867 million, translating to pro forma EPS of $2.40, a 30% increase from the previous year. GAAP net income was $704 million ($1.95 per share).

Procedure Growth: Total procedure growth was 20%, with da Vinci procedures up 19% and ION procedures up 52%.

Installed Base: The installed base of da Vinci systems increased by 13% to nearly 10,800 systems, while ION systems grew by 30% to approximately 950.

Utilization: Average system utilization increased by 4% for da Vinci and 14% for ION.

Capital Placements: 427 da Vinci systems were placed, including 240 da Vinci V systems, reflecting strong domestic demand.

2Strategic Updates and Business Highlights

da Vinci V Launch: The first full quarter of da Vinci V availability led to increased demand for system upgrades and dual consoles, with positive early feedback from international placements in Japan and Europe.

User Conference: The tenth annual Intuitive 360 user conference attracted over 1,100 healthcare professionals, emphasizing the focus on improving patient outcomes and operational efficiency.

Software Updates: Received FDA clearance for software updates enhancing da Vinci V capabilities, including remote deployment features.

Refurbished XI Systems: Plans to offer refurbished Xi systems to expand access in cost-sensitive markets, with 20 units sold so far.

3Forward Guidance and Outlook

Procedure Growth: Updated full-year 2025 da Vinci procedure growth guidance to 17-17.5%.

Gross Margin: Pro forma gross margin guidance for 2025 is now 67-67.5%, improved due to cost efficiencies and lower tariff impacts.

Operating Expenses: Expected growth of 11-13% in operating expenses, driven by increased headcount and facility costs.

Tax Rate: Estimated pro forma income tax rate for 2025 adjusted to 21-22%.

4Bad News, Challenges, or Points of Concern

Bariatric Surgery Decline: Continued downward pressure on bariatric procedures, with no clear indication of recovery from surgeons, attributed to the impact of GLP-1 medications.

China Market Challenges: Competitive pressures and slow tender processes in China, with price pressures affecting both capital and instrumentation revenue.

Utilization Concerns: Mixed dynamics in US utilization growth, particularly in smaller community hospitals, which may lag behind larger institutions adopting da Vinci V.

5Notable Q&A Insights

Sustainability of Procedure Growth: Management indicated that the strong procedure growth in Q3 was supported by increased demand for da Vinci V and improvements in operational efficiency, though future growth may vary by market segment.

Refurbished XI Strategy: The refurbished XI systems are seen as a critical component for cost-sensitive customers, with potential for growth in both US and international markets.

Digital Integration: The hub and digital tools are expected to enhance da Vinci V performance and drive adoption, with ongoing development in AI and machine learning to optimize surgical outcomes.

Cardiac Surgery Potential: Management highlighted opportunities in cardiac surgery, where da Vinci V's capabilities could address unmet needs in patient care. This earnings call reflects a strong quarter for Intuitive Surgical, with robust growth in procedures and strategic advancements, although challenges in specific markets and segments remain a concern for future performance.